## User

This is the beginning of a team meeting to discuss your research project. This is a meeting with the team lead, Principal Investigator (Alzheimer's KG), and the following team members: Scientific Critic (AlzKB), Tech Lead (AlzKB Engineering), Data Curator (AlzKB Ontologies), Data Quality & Validation Scientist.

Here is the agenda for the meeting:

Task: Build a scalable, retrieval-optimized Knowledge Graph for Alzheimer's Disease research.

TASK: Define the Technical Specification for AlzKB.
The team must agree on the architectural foundation before implementation.

OUTPUT REQUIREMENTS:
1. SCHEMA CORE: Define top 6 Entity Types and 6 Edge Types (Must be biologically specific, e.g., 'phosphorylates' not 'interacts').
2. DATA STRATEGY: Select 4 priority Data Sources (e.g., ADNI) and define the Evidence Scoring mechanism (e.g., 'Clinical vs. Preclinical').
3. SUCCESS METRICS: Define 3 quantitative KPIs for coverage and precision.

CONSTRAINTS: Be specific. No fluff. Prioritize AD-specific nuances (e.g., Tau isoforms).


Here are the agenda questions that must be answered:

1. PROPOSE SCHEMA: List the top 6 Node Types and 6 specific Edge Types essential for AD reasoning. Justify why these support hypothesis generation.

2. DATA INGESTION: Which 4 external databases are critical for Day 1 import? How will we handle conflicting evidence (e.g., human vs. mouse data) in the graph structure?

3. VALIDATION: Define the 'Gold Standard'. How exactly will we measure Precision and Recall? (e.g., 'Manually curated dataset of 100 triples').

Principal Investigator (Alzheimer's KG) will convene the meeting. Then, each team member will provide their thoughts on the discussion one-by-one in the order above. After all team members have given their input, Principal Investigator (Alzheimer's KG) will Synthesize team inputs. 1. Identify agreements vs. conflicts. 2. Resolve conflicts using provided evidence; favor data over opinion. 3. Decide the agenda status. 4. Ask 1 concrete question to clarify ambiguity if needed. Be concise.. This will continue for 2 rounds. Once the discussion is complete, Principal Investigator (Alzheimer's KG) will Summarize the meeting log strictly in Markdown: ## Decisions (with Rationale)
## Unresolved Issues
## Next Steps
## Answer to Agenda
Ignore pleasantries. Ensure all technical constraints are captured..

## User

Principal Investigator (Alzheimer's KG), please provide your initial thoughts on the agenda as well as any questions you have to guide the discussion among the team members.

## Principal Investigator (Alzheimer's KG)

**Principal Investigator (Alzheimer's KG): Initial Thoughts & Guidance**

**1. Schema Core:**
- We must ensure our Entity and Edge types are granular enough for AD-specific reasoning and mechanistic queries (e.g., distinguishing between tau isoforms, not generic 'protein').
- Edges must capture directionality and biological specificity (e.g., 'phosphorylates', 'expressed_in', 'biomarker_for').
- Node types should enable queries spanning clinical, molecular, and imaging domains.

**2. Data Ingestion:**
- Only high-confidence, AD-relevant sources should be prioritized for Day 1 (e.g., ADNI for imaging/clinical, AMP-AD for omics, GWAS Catalog for genetic risk, and UniProt for protein function/pathology).
- Conflicting evidence (e.g., human vs. mouse, or contradictory study results) must be explicitly modeled, not suppressed—potentially via 'evidence' nodes or edge properties.

**3. Validation:**
- Gold Standard: Must be a manually curated, multi-modal set of AD-relevant triples (e.g., tau phosphorylation sites, APOE genotype-phenotype links, amyloid imaging findings).
- Precision should be prioritized over recall to avoid spurious associations. Recall is still relevant for coverage assessment.
- KPIs must be quantitative, reproducible, and relevant for both breadth (coverage of known AD biology) and correctness (precision vs. gold standard).

**Key Questions to Guide Discussion:**
- For schema: Are there any essential entity or edge types missing for AD-specific hypothesis generation?
- For data: Which sources provide the highest-confidence, multi-modal data for AD? How do we represent and score conflicting evidence?
- For validation: What constitutes an authoritative 'gold standard' for AD knowledge? How do we ensure our KPIs are both stringent and actionable?

**Next: Scientific Critic (AlzKB), please provide your input on the schema, data sources, and validation approach.**

## User

Scientific Critic (AlzKB), please provide your thoughts on the discussion (round 1 of 2). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Scientific Critic (AlzKB)

**Scientific Critic (AlzKB): Input (Round 1)**

**1. Schema Core:**
- **Entity Types (Nodes):**
  1. Protein (with explicit isoforms, e.g., MAPT-P301L, Abeta40, Abeta42)
  2. Gene (HGNC-compliant, with species tag)
  3. Variant (e.g., rsID, including zygosity)
  4. Pathological Process (e.g., 'tau aggregation', 'amyloid deposition')
  5. Clinical Phenotype (e.g., 'memory impairment', 'Braak stage')
  6. Imaging Biomarker (e.g., 'PiB-PET signal', 'hippocampal atrophy')

  *Justification:* These nodes allow mechanistic tracing from genotype to phenotype and support multi-modal hypothesis generation (e.g., linking APOE4 genotype to amyloid PET signal via Abeta pathology).

- **Edge Types (Biologically Specific):**
  1. phosphorylates (e.g., GSK3B phosphorylates MAPT at S396)
  2. cleaves (e.g., BACE1 cleaves APP)
  3. upregulates/downregulates expression (e.g., Variant upregulates APP)
  4. causes_pathology (e.g., Abeta42 oligomers cause synaptic loss)
  5. biomarker_for (e.g., PiB-PET is biomarker_for amyloid deposition)
  6. associated_with_phenotype (e.g., APOE4 associated_with_phenotype 'early onset AD')

  *Justification:* All edges are directional and mechanistically interpretable—no generic 'interacts_with' or 'associated_with'.

**2. Data Ingestion:**
- **Priority Data Sources:**
  1. ADNI (clinical, imaging, biomarker)
  2. AMP-AD Knowledge Portal (multi-omics, transcriptomics/proteomics)
  3. GWAS Catalog (human genetic associations)
  4. UniProt/PhosphoSitePlus (protein function, PTMs)

- **Conflicting Evidence Handling:**
  - Every triple must be tagged with species, evidence type (clinical, preclinical, in vitro), and provenance (PubMed ID or dataset accession).
  - Contradictory findings (e.g., mouse vs. human, or opposing study results) are not merged—each is retained with its provenance and scored for evidence strength (e.g., clinical > preclinical > in vitro).

**3. Validation:**
- **Gold Standard:**
  - A hand-curated set of 100 mechanistically specific triples, covering all node/edge types, drawn from recent AD review articles and consensus guidelines (with PubMed links).
  - Example: "GSK3B phosphorylates MAPT at S396 (PMID: 12345678)", "APOE4 associated_with_phenotype 'increased amyloid burden' (PMID: 23456789)".

- **KPIs (Quantitative):**
  1. Precision@100: Fraction of top 100 triples matching gold standard.
  2. Recall@100: Fraction of gold standard triples recovered in top 100 graph triples.
  3. Entity Resolution Error Rate: % of ambiguous/mis-mapped entities (e.g., Abeta40 vs. Abeta42) in a 50-triple audit.

**Summary:**  
- No generic or ambiguous schema elements.
- Strict provenance and evidence scoring.
- Quantitative, gold-standard-based validation only.

**Next: Tech Lead (AlzKB Engineering), your input.**

## User

Tech Lead (AlzKB Engineering), please provide your thoughts on the discussion (round 1 of 2). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Tech Lead (AlzKB Engineering)

**Tech Lead (AlzKB Engineering): Input (Round 1)**

**1. Schema Core:**
- **Entity Types (Nodes):**
  1. Protein (with isoform and PTM annotation, e.g., MAPT-P301L, Abeta42, phosphorylated-tau)
  2. Gene (HGNC ID, species-specific)
  3. Genetic Variant (rsID, zygosity, population frequency)
  4. Pathological Process (explicit, e.g., 'tau hyperphosphorylation', 'amyloid plaque formation')
  5. Clinical Phenotype (standardized, e.g., NINCDS-ADRDA criteria, Braak stage, MMSE score)
  6. Imaging Biomarker (e.g., PiB-PET, FDG-PET, hippocampal volume)

  *Justification:* This set supports both mechanistic and translational queries, and enables cross-modal linkage (e.g., genotype → protein → pathology → imaging → clinical).

- **Edge Types (Specific, Directional):**
  1. phosphorylates (Protein → Protein, with site annotation)
  2. cleaves (Protein → Protein, with cleavage site)
  3. upregulates/downregulates_expression (Variant/Gene/Protein → Gene/Protein, context-specific)
  4. induces_pathology (Protein/Variant → Pathological Process)
  5. biomarker_for (Imaging/Protein → Pathological Process/Clinical Phenotype)
  6. associated_with_phenotype (Gene/Variant/Protein → Clinical Phenotype, with effect size if available)

  *Justification:* These edges are retrieval-optimized and map directly to AD mechanisms and clinical endpoints.

**2. Data Ingestion:**
- **Priority Data Sources:**
  1. ADNI (clinical, imaging, CSF biomarkers)
  2. AMP-AD (multi-omics: RNA-seq, proteomics)
  3. GWAS Catalog (AD-specific GWAS, with effect sizes)
  4. UniProt/PhosphoSitePlus (protein function, PTMs, isoforms)

- **Conflicting Evidence Handling:**
  - All edges must include metadata: species, evidence type (clinical/preclinical/in vitro), cohort, and provenance (PMID/dataset).
  - Contradictory evidence is modeled as parallel edges with distinct evidence scores. No merging or suppression.
  - Evidence Scoring: Clinical > Preclinical (animal) > In vitro. Score is an edge property, allowing query-based filtering (e.g., "show only human clinical evidence").

**3. Validation:**
- **Gold Standard:**
  - 100 manually curated, AD-relevant triples, covering all schema types, sourced from consensus reviews and guidelines.
  - Each triple must have explicit provenance (PubMed ID, dataset accession).

- **KPIs:**
  1. Precision@100: % of top 100 triples matching gold standard.
  2. Recall@100: % of gold standard triples present in graph.
  3. Entity Disambiguation Rate: % of correctly resolved isoforms/biomarkers in a 50-triple audit.

**Additional Technical Note:**
- Schema must be enforced at the database level (e.g., Neo4j constraints), and ETL pipelines must support incremental updates and evidence re-scoring.
- Entity mapping across modalities (e.g., linking MRI findings to Braak stage) must be prioritized in pipeline design.

**Next: Data Curator (AlzKB Ontologies), your input.**

## User

Data Curator (AlzKB Ontologies), please provide your thoughts on the discussion (round 1 of 2). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Data Curator (AlzKB Ontologies)

**Data Curator (AlzKB Ontologies): Input (Round 1)**

**1. Schema Core:**
- **Entity Types (Nodes):**
  1. Protein (with unambiguous UniProt ID, isoform/variant/PTM annotation; e.g., MAPT_HUMAN isoform 2, Abeta42)
  2. Gene (HGNC ID, species tag)
  3. Genetic Variant (dbSNP rsID, zygosity, population context)
  4. Pathological Process (mapped to GO Biological Process or MONDO where possible; e.g., 'tau aggregation' [GO:0051783])
  5. Clinical Phenotype (mapped to HPO/UMLS; e.g., 'memory impairment' [HP:0002354], 'Braak stage' [UMLS:C0750900])
  6. Imaging Biomarker (RadLex/LOINC/CPT code; e.g., 'PiB-PET SUVR', 'hippocampal atrophy' [RadLex:RID10341])

  *Justification:* Use of standardized vocabularies ensures cross-dataset interoperability and minimizes semantic drift. Explicit mapping to ontologies enables integration with external resources and supports FAIR principles.

- **Edge Types (Biologically Specific, Ontology-Mapped):**
  1. phosphorylates (RO:0002411, with residue annotation)
  2. cleaves (RO:0002211, with cleavage site)
  3. regulates_expression_of (RO:0002212, up/down directionality as property)
  4. induces_pathology (custom, or MONDO/GO if available)
  5. is_biomarker_for (custom, mapped to OBO Relations Ontology if possible)
  6. associated_with_phenotype (SIO:000628, with effect size/context as property)

  *Justification:* Each edge type is mapped to an OBO Foundry or SIO relation where available, supporting automated reasoning and downstream semantic queries.

**2. Data Ingestion:**
- **Priority Data Sources:**
  1. ADNI (clinical, imaging, CSF/biomarker; mapped to LOINC/RadLex/UMLS)
  2. AMP-AD (omics, transcriptomics/proteomics; mapped to Ensembl/UniProt)
  3. GWAS Catalog (variants, mapped to dbSNP/HGNC)
  4. UniProt/PhosphoSitePlus (protein function, PTMs; mapped to UniProt/PSP IDs)

- **Conflicting Evidence Handling:**
  - All imported statements must include: species, evidence type (mapped to ECO), provenance (PubMed ID/dataset), and evidence strength (clinical > preclinical > in vitro).
  - Contradictory evidence is retained as separate edges, each with full provenance and evidence score (as an edge property). No collapsing or averaging.
  - Evidence scoring schema: ECO:0000218 (clinical), ECO:0000179 (animal model), ECO:0000006 (cell line/in vitro).

**3. Validation:**
- **Gold Standard:**
  - 100 manually curated, ontology-mapped triples, covering all node/edge types, with explicit mapping to reference ontologies and PubMed/dataset provenance.
  - Example: "GSK3B (UniProt: P49840) phosphorylates MAPT (UniProt: P10636-8) at S396 [RO:0002411], PMID:12345678"

- **KPIs:**
  1. Precision@100: % of top 100 triples matching gold standard, ontology-mapped.
  2. Recall@100: % of gold standard ontology-mapped triples present in graph.
  3. Ontology Mapping Accuracy: % of nodes/edges correctly mapped to standard vocabularies in a 50-triple audit.

**Additional Notes:**
- Schema constraints must enforce ontology compliance (e.g., no unmapped clinical phenotypes).
- All ETL and curation pipelines must support versioning and provenance tracking for reproducibility and update traceability.

**Next: Data Quality & Validation Scientist, your input.**

## User

Data Quality & Validation Scientist, please provide your thoughts on the discussion (round 1 of 2). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Data Quality & Validation Scientist

**Data Quality & Validation Scientist: Input (Round 1)**

**1. Schema Core:**
- **Entity Types (Nodes):**
  1. Protein (UniProt ID, isoform/PTM annotation required)
  2. Gene (HGNC ID, species-specific)
  3. Genetic Variant (rsID, zygosity, population context)
  4. Pathological Process (GO/MONDO mapped)
  5. Clinical Phenotype (HPO/UMLS mapped, with scale/criteria)
  6. Imaging Biomarker (RadLex/LOINC mapped, quantitative value as property)

  *Rationale:* These types are sufficiently granular for AD-specific mechanistic and translational reasoning, and enforce unambiguous entity resolution across modalities.

- **Edge Types (Biologically Specific, Directional):**
  1. phosphorylates (Protein → Protein, with site annotation)
  2. cleaves (Protein → Protein, with cleavage site)
  3. regulates_expression_of (up/down, Variant/Gene/Protein → Gene/Protein, with context)
  4. induces_pathology (Protein/Variant → Pathological Process, with evidence type)
  5. is_biomarker_for (Imaging/Protein → Pathological Process/Clinical Phenotype, with quantitative threshold if applicable)
  6. associated_with_phenotype (Gene/Variant/Protein → Clinical Phenotype, effect size/property required)

  *Rationale:* All edges must be directional, evidence-tagged, and mapped to standard ontologies where possible. No generic or ambiguous relationships are allowed.

**2. Data Ingestion:**
- **Priority Data Sources:**
  1. ADNI (clinical, imaging, CSF biomarkers)
  2. AMP-AD (omics, transcriptomics, proteomics)
  3. GWAS Catalog (AD-specific variants, effect sizes)
  4. UniProt/PhosphoSitePlus (protein isoforms, PTMs)

- **Conflicting Evidence Handling:**
  - Each edge must be annotated with: species, evidence type (ECO code), provenance (PMID/dataset), and evidence score (clinical > preclinical > in vitro).
  - Contradictory evidence is not collapsed; all statements are retained with full provenance and scored accordingly.
  - Evidence scoring is explicit and queryable (e.g., edge property: evidence_score = 3 for clinical, 2 for preclinical, 1 for in vitro).

**3. Validation:**
- **Gold Standard:**
  - 100 manually curated triples, covering all schema types, with explicit ontology mapping and full provenance (PubMed/dataset).
  - Gold standard must be reviewed by at least two domain experts for adjudication of ambiguous cases.

- **KPIs:**
  1. Precision@100: % of top 100 graph triples matching gold standard (manual review).
  2. Recall@100: % of gold standard triples present in graph.
  3. Ontology Mapping Error Rate: % of node/edge mis-mappings in a 50-triple audit.

**Additional Quality Constraints:**
- All imported data must pass automated schema validation (ontology mapping, evidence/provenance completeness).
- Gold standard triples must be versioned and updated quarterly to reflect new AD consensus findings.
- Human-in-the-loop review for ambiguous or low-confidence associations is mandatory before production release.

**Summary:**  
- Strong agreement with previous team members on schema, data sources, and evidence handling.
- Emphasis on explicit evidence scoring, ontology compliance, and rigorous manual validation.
- Suggest quarterly review and update of gold standard to maintain relevance.

**Next: Principal Investigator (Alzheimer's KG), please synthesize the team inputs.**

## User

This concludes round 1 of 2 of discussion. Principal Investigator (Alzheimer's KG), please Synthesize team inputs. 1. Identify agreements vs. conflicts. 2. Resolve conflicts using provided evidence; favor data over opinion. 3. Decide the agenda status. 4. Ask 1 concrete question to clarify ambiguity if needed. Be concise..

## Principal Investigator (Alzheimer's KG)

**SYNTHESIS OF TEAM INPUTS (ROUND 1)**

**1. Agreements:**
- **Entity Types:** All team members converge on the same 6 core node types: Protein (with isoform/PTM detail), Gene (HGNC/species), Genetic Variant (rsID, zygosity), Pathological Process (GO/MONDO mapped), Clinical Phenotype (HPO/UMLS mapped), Imaging Biomarker (RadLex/LOINC mapped).
- **Edge Types:** Universal agreement on 6 biologically specific, directional relationships: phosphorylates, cleaves, regulates_expression_of (up/down), induces_pathology, is_biomarker_for, associated_with_phenotype. All must be ontology-mapped where possible.
- **Data Sources:** Consensus on ADNI, AMP-AD, GWAS Catalog, UniProt/PhosphoSitePlus as Day 1 priorities.
- **Conflicting Evidence:** All agree on explicit modeling of evidence (species, evidence type, provenance, evidence score), with no collapsing or averaging of contradictory findings.
- **Validation:** All advocate for a 100-triple, manually curated, ontology-mapped gold standard with full provenance. KPIs: Precision@100, Recall@100, and an ontology/entity mapping accuracy/error rate.

**2. Conflicts:**
- **Edge Naming:** Minor variation (e.g., 'causes_pathology' vs. 'induces_pathology' vs. 'induces_pathology'). Consensus leans toward 'induces_pathology' for alignment with OBO/GO.
- **Evidence Scoring:** All agree on clinical > preclinical > in vitro, but terminology for evidence properties (e.g., ECO codes) is more explicit in ontology/data quality roles. Adopt ECO code mapping for consistency.
- **Ontology Mapping:** Stronger emphasis from Data Curator/Data Quality on strict ontology mapping and schema enforcement. Adopt this as a non-negotiable constraint.

**3. Agenda Status:**  
- **Schema, data sources, and validation framework are agreed in principle.**
- **Minor terminology and implementation details remain (e.g., edge naming, evidence property schema).**

**4. Clarifying Question:**  
- For **Data Curator** and **Data Quality & Validation Scientist**:  
  Should we enforce ontology mapping at ingestion (blocking unmapped terms), or allow provisional ingestion with subsequent curation? Please specify the operational trade-offs.

**Proceed to round 2.**

## User

Scientific Critic (AlzKB), please provide your thoughts on the discussion (round 2 of 2). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Scientific Critic (AlzKB)

**Scientific Critic (AlzKB): Input (Round 2)**

**Edge Naming:**  
Support the consensus to use 'induces_pathology' for edge naming, as it aligns with OBO/GO and avoids ambiguity present in 'causes_pathology'.

**Ontology Mapping Enforcement:**  
Strongly recommend **blocking unmapped terms at ingestion**. Allowing provisional ingestion risks semantic drift, proliferation of ambiguous nodes, and downstream curation bottlenecks. In AD, where entity disambiguation (e.g., tau isoforms, Abeta peptides) is critical, strict enforcement ensures only high-confidence, interoperable data enters the graph. This also prevents circular reasoning in evaluation, as only well-defined entities are scored.

**Operational Trade-off:**  
Blocking unmapped terms may slow ingestion but guarantees data quality and minimizes rework. Provisional ingestion risks polluting the graph with ambiguous or irreconcilable terms, undermining trust and downstream analytics.

**Summary:**  
- Endorse strict ontology mapping enforcement at ingestion.
- No further schema or data source objections.
- Recommend periodic review of ontology coverage to identify and address gaps proactively.

**Next: Tech Lead (AlzKB Engineering), your input.**

## User

Tech Lead (AlzKB Engineering), please provide your thoughts on the discussion (round 2 of 2). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Tech Lead (AlzKB Engineering)

**Tech Lead (AlzKB Engineering): Input (Round 2)**

**Edge Naming:**  
Agree with the team: standardize on 'induces_pathology' for edge naming, mapped to OBO/GO where possible.

**Ontology Mapping Enforcement:**  
From an engineering and scalability perspective, I support **blocking unmapped terms at ingestion**. This approach:
- Prevents downstream technical debt (avoiding the need for later re-mapping or retroactive curation).
- Ensures schema constraints can be strictly enforced at the database level (e.g., Neo4j constraints, validation scripts).
- Facilitates reproducibility and confidence in API outputs, as all entities/relations are guaranteed to be ontology-backed.

**Operational Trade-off:**  
Blocking unmapped terms may require more up-front effort in ETL and may slow initial ingestion. However, it avoids the risk of ambiguous node proliferation and simplifies maintenance, querying, and downstream analytics. Provisional ingestion could be considered for a separate, clearly labeled "staging" graph, but not in the production KG.

**Additional Note:**  
- Recommend automated ingestion pipeline checks for ontology mapping (fail-fast), with error logs routed to curators for rapid resolution.
- Suggest maintaining a prioritized backlog of unmapped but high-value terms for ontology extension or mapping requests.

**No further objections.**  
**Next: Data Curator (AlzKB Ontologies), your input.**

## User

Data Curator (AlzKB Ontologies), please provide your thoughts on the discussion (round 2 of 2). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Data Curator (AlzKB Ontologies)

**Data Curator (AlzKB Ontologies): Input (Round 2)**

**Ontology Mapping Enforcement:**  
I fully support **blocking unmapped terms at ingestion** for the production knowledge graph. This is essential for:
- Maintaining semantic integrity and interoperability.
- Preventing the introduction of ambiguous or non-standard entities, which are particularly problematic in AD (e.g., generic “tau” vs. specific isoforms).
- Enabling automated reasoning and reliable cross-dataset queries.

**Operational Trade-off:**  
Blocking unmapped terms will slow initial data throughput, especially for novel or rare AD terms not yet covered in standard ontologies. However, the alternative—provisional ingestion—creates significant downstream curation burden, increases the risk of semantic drift, and complicates both validation and user trust.

**Mitigation Strategy:**  
- Implement a rapid triage and mapping workflow for unmapped terms, with a fast feedback loop to ontology maintainers or custom extension pipelines.
- Maintain a transparent, versioned backlog of unmapped terms with justifications and mapping status, so the team can prioritize ontology updates.

**Edge Naming:**  
Agree with the consensus on 'induces_pathology' as the standard, OBO/GO-aligned edge.

**Summary:**  
- Enforce ontology mapping at ingestion for production KG.
- Use a triage process for unmapped terms.
- No further schema, data, or validation objections.

**Next: Data Quality & Validation Scientist, your input.**

## User

Data Quality & Validation Scientist, please provide your thoughts on the discussion (round 2 of 2). If you do not have anything new or relevant to add, you may say "pass". Remember that you can and should (politely) disagree with other team members if you have a different perspective.

## Data Quality & Validation Scientist

**Data Quality & Validation Scientist: Input (Round 2)**

**Ontology Mapping Enforcement:**  
I strongly support **blocking unmapped terms at ingestion** for the production graph. This is critical for:
- Ensuring all entities and relationships are unambiguous and interoperable.
- Preventing downstream error propagation and inflated entity resolution error rates.
- Maintaining the integrity of gold standard evaluation and precision/recall metrics (since unmapped terms would otherwise be unscorable).

**Operational Trade-off:**  
Blocking unmapped terms may temporarily reduce coverage, especially for emerging or less-studied AD concepts. However, this is preferable to the risk of semantic contamination and loss of trust in graph outputs.  
- Provisional ingestion could be allowed in a separate, non-production "staging" environment for ontology extension and review, but not in the main KG.

**Mitigation:**  
- Implement automated rejection and logging of unmapped terms, with curator notification for rapid mapping or escalation.
- Regularly review the backlog of unmapped terms and prioritize based on research relevance and user demand.

**Edge Naming:**  
Agree with consensus: use 'induces_pathology', mapped to OBO/GO.

**Summary:**  
- Enforce strict ontology mapping at ingestion for production.
- Use a staging area for provisional terms only if needed.
- No remaining objections on schema, data sources, or validation.

**Ready for PI synthesis and final agenda summary.**

## User

Principal Investigator (Alzheimer's KG), please Summarize the meeting log strictly in Markdown: ## Decisions (with Rationale)
## Unresolved Issues
## Next Steps
## Answer to Agenda
Ignore pleasantries. Ensure all technical constraints are captured..

As a reminder, here is the agenda for the meeting:

Task: Build a scalable, retrieval-optimized Knowledge Graph for Alzheimer's Disease research.

TASK: Define the Technical Specification for AlzKB.
The team must agree on the architectural foundation before implementation.

OUTPUT REQUIREMENTS:
1. SCHEMA CORE: Define top 6 Entity Types and 6 Edge Types (Must be biologically specific, e.g., 'phosphorylates' not 'interacts').
2. DATA STRATEGY: Select 4 priority Data Sources (e.g., ADNI) and define the Evidence Scoring mechanism (e.g., 'Clinical vs. Preclinical').
3. SUCCESS METRICS: Define 3 quantitative KPIs for coverage and precision.

CONSTRAINTS: Be specific. No fluff. Prioritize AD-specific nuances (e.g., Tau isoforms).


As a reminder, here are the agenda questions that must be answered:

1. PROPOSE SCHEMA: List the top 6 Node Types and 6 specific Edge Types essential for AD reasoning. Justify why these support hypothesis generation.

2. DATA INGESTION: Which 4 external databases are critical for Day 1 import? How will we handle conflicting evidence (e.g., human vs. mouse data) in the graph structure?

3. VALIDATION: Define the 'Gold Standard'. How exactly will we measure Precision and Recall? (e.g., 'Manually curated dataset of 100 triples').

Your summary should take the following form.

### Agenda

Restate the agenda in your own words.

### Team Member Input

Summarize all of the important points raised by each team member. This is to ensure that key details are preserved for future meetings.

### Recommendation

Provide your expert recommendation regarding the agenda. You should consider the input from each team member, but you must also use your expertise to make a final decision and choose one option among several that may have been discussed. This decision can conflict with the input of some team members as long as it is well justified. It is essential that you provide a clear, specific, and actionable recommendation. Please justify your recommendation as well.

### Answers

For each agenda question, please provide the following:

Answer: A specific answer to the question based on your recommendation above.

Justification: A brief explanation of why you provided that answer.

### Next Steps

Outline the next steps that the team should take based on the discussion.

## Principal Investigator (Alzheimer's KG)

### Agenda

Define the technical specification for the Alzheimer’s Knowledge Base (AlzKB) Knowledge Graph. This includes: (1) establishing a biologically precise schema (top 6 node and edge types) optimized for AD-specific reasoning; (2) selecting 4 high-confidence, multi-modal data sources and specifying an explicit evidence scoring and conflict-handling strategy; (3) setting quantitative KPIs and a gold standard for precision and recall. All technical constraints must prioritize AD-specific nuances (e.g., tau isoforms, evidence provenance, ontology mapping).

---

### Team Member Input

**Scientific Critic (AlzKB):**
- Advocated for granular, AD-specific node/edge types (e.g., tau isoforms, explicit PTMs).
- Stressed strict evidence tagging (species, evidence type, provenance) and non-collapsing of conflicting evidence.
- Supported blocking unmapped terms at ingestion to prevent semantic drift.

**Tech Lead (AlzKB Engineering):**
- Emphasized schema enforcement at the database level and fail-fast ETL pipelines.
- Supported strict ontology mapping at ingestion for production; suggested a possible staging area for unmapped terms.
- Highlighted the need for automated checks and a backlog for unmapped but high-value terms.

**Data Curator (AlzKB Ontologies):**
- Required all nodes/edges to be mapped to standard ontologies (HGNC, UniProt, GO, HPO, UMLS, RadLex, LOINC, SIO, ECO).
- Supported blocking unmapped terms at ingestion, with a rapid triage process for ontology extension.
- Advocated for transparent versioning and tracking of unmapped terms.

**Data Quality & Validation Scientist:**
- Prioritized data quality, unambiguous entity resolution, and evidence/provenance completeness.
- Strongly supported blocking unmapped terms at ingestion and maintaining a staging area for provisional terms if needed.
- Recommended quarterly review and update of the gold standard.

---

### Recommendation

**Adopt a strictly enforced, ontology-mapped schema with 6 biologically precise node and edge types, blocking unmapped terms at ingestion for production.**  
- All imported data must be mapped to standard ontologies (HGNC, UniProt, GO, HPO, UMLS, RadLex, LOINC, SIO, ECO).
- Use ADNI, AMP-AD, GWAS Catalog, and UniProt/PhosphoSitePlus as Day 1 data sources.
- All edges must carry explicit evidence metadata (species, evidence type, provenance, evidence score).
- Contradictory evidence is modeled as parallel edges with full provenance and evidence scoring.
- Validation is based on a 100-triple, manually curated, ontology-mapped gold standard; KPIs are Precision@100, Recall@100, and Ontology Mapping Error Rate.
- Maintain a rapid triage process and backlog for unmapped terms, but do not admit them into the production KG.

**Justification:**  
This approach maximizes data quality, semantic interoperability, and hypothesis generation capability, while minimizing technical debt and ambiguity. It is aligned with FAIR principles and supports robust, reproducible downstream analytics.

---

### Answers

#### 1. PROPOSE SCHEMA

**Answer:**  
**Node Types:**  
1. Protein (UniProt ID, isoform/PTM annotated)  
2. Gene (HGNC ID, species-specific)  
3. Genetic Variant (rsID, zygosity, population context)  
4. Pathological Process (GO/MONDO mapped)  
5. Clinical Phenotype (HPO/UMLS mapped)  
6. Imaging Biomarker (RadLex/LOINC mapped)  

**Edge Types:**  
1. phosphorylates (Protein → Protein, site-specific, RO:0002411)  
2. cleaves (Protein → Protein, cleavage site, RO:0002211)  
3. regulates_expression_of (up/down, Variant/Gene/Protein → Gene/Protein, RO:0002212)  
4. induces_pathology (Protein/Variant → Pathological Process, OBO/GO mapped)  
5. is_biomarker_for (Imaging/Protein → Pathological Process/Clinical Phenotype, custom/OBO mapped)  
6. associated_with_phenotype (Gene/Variant/Protein → Clinical Phenotype, SIO:000628)  

**Justification:**  
These types capture the mechanistic, translational, and clinical axes essential for AD hypothesis generation, while ensuring semantic precision and interoperability.

---

#### 2. DATA INGESTION

**Answer:**  
**Day 1 Data Sources:**  
1. ADNI (clinical, imaging, CSF biomarkers)  
2. AMP-AD (omics, transcriptomics, proteomics)  
3. GWAS Catalog (AD-specific variants, effect sizes)  
4. UniProt/PhosphoSitePlus (protein isoforms, PTMs)  

**Evidence Handling:**  
- All statements must be tagged with species, evidence type (ECO code), provenance (PubMed/dataset), and evidence score (clinical > preclinical > in vitro).
- Contradictory evidence is retained as separate, fully annotated edges; no collapsing or averaging.
- Unmapped terms are blocked from production ingestion; maintained in a backlog for ontology extension.

**Justification:**  
These sources maximize coverage of AD-relevant modalities. Explicit evidence modeling preserves data integrity and supports nuanced querying.

---

#### 3. VALIDATION

**Answer:**  
**Gold Standard:**  
- 100 manually curated, ontology-mapped triples covering all schema types, with explicit provenance (PubMed/dataset).
- Reviewed by at least two domain experts and updated quarterly.

**KPIs:**  
1. Precision@100: % of top 100 graph triples matching gold standard.  
2. Recall@100: % of gold standard triples present in graph.  
3. Ontology Mapping Error Rate: % of node/edge mis-mappings in a 50-triple audit.

**Justification:**  
This ensures both breadth and correctness, with rigorous, reproducible metrics and continuous quality improvement.

---

### Next Steps

1. Finalize and document the schema (node/edge types, ontology mappings, evidence properties).
2. Implement ETL pipelines with fail-fast ontology mapping enforcement and error logging.
3. Curate and version the 100-triple gold standard.
4. Set up a triage workflow and backlog for unmapped terms.
5. Begin Day 1 data ingestion from prioritized sources, blocking unmapped terms from production.
6. Schedule quarterly gold standard review and update cycle.

